There have been continual evolutions in cure of Chalmydia infections. And there are medications which have been made available to the patients. There are PDT, Patient delivered partner therapies wherein one of the sex partner can take medicines for the other without being physically examined by a doctor.
There are generic antibiotics such as Erythromycin or Ofloxacin to cure Chlamydia infection. Doxycycline is another widely prescribed antibiotic for Chlamydia infections. A weekly prescription is a general cure of the disease. Azithromycin, however remains, apparently the most effective antibiotic against the disease. It belongs to a new group of antibiotics called Azalides which have a nitgrogen compound in the fifteen ring chemical structure.
A systematic and detailed research experiment conducted in the United States on 457 patients screened from from medical houses, adolescent health clinics etc all of whom were afflicted with Chlamydia infection. The number constituted of 158 males and remaining females enrolled in 21 centres in the US. Patients with any history of sensitivity or allergy to the drugs were excluded out. Also patients with epididymitis, proctitis or other serious infections, alcohol or drug abuse or were pregnant and lactating were not enrolled in the experiment.
Patients were given either one dosage of 1 gm Azithromycin or two dosages of Doxycycline daily for seven days in a row. Azithromycin was given to 237 patients (152 female, and 85 males), and Doxycycline was used in 220 patients (147 female and 73 male). There were periodical evaluations conducted on a weekly basis for over a month and patients with unprotected sexual exposure were removed from the study database. Eventually only 141 Azithromycin patients and 125 Doxycycline-treated patients were available for the experiment analysis.
After twenty nine days from the beginning of the tests, culture samples were collected. The results were very good – only one patient from the Doxycycline group and none of the Azithromycin group was detected with a positive result for Chlamydia infection.
There were several follow ups done to keep gauging the physical symptoms of continuing of the trachomatis in discharges and culture specimen and towards the end it was established that 98 percent of the male patients and 97 percent of the female patients had responded to Azithromycin in comparison to 95 percent female patients and 91 male patients to Doxycycline. Azithromycin marked a three percent improvement edge over Doxycycline. Azithromycin also maintained an edge in fewer side effects. While Azithromycin had 17 percent candidates with side effects Doxycycline had 20 percent cases of side effects.